Australian Committee: Slow Down On Biosimilar Substitution
This article was originally published in PharmAsia News
Executive Summary
Moves by the Australian government to allow automatic pharmacist substitution of biosimilars have created broad concerns in the industry related to product safety, quality and equivalence, but these now appear to have been taken on board, with a wide consultation process planned on the move and biosimilar regulation.